Cancer statistics in China, 2015
2016/01/25 by Wanqing Chen, Rongshou Zheng, Peter D. Baade +6 · 36 citations
Medicine · Economics, Econometrics and Finance · #Global Cancer Incidence and Screening #Colorectal Cancer Screening and Detection #Healthcare Systems and Reforms
paper · pdf · doi:10.3322/caac.21338
Abstract
With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Citations
Cited by
- Deep learning‐based AI model for signet‐ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer
- <scp>PET</scp>/<scp>CT</scp> and <scp>MRI</scp> for Identifying Axillary Lymph Node Metastases in Breast Cancer Patients: Systematic Review and Meta‐Analysis
- LvHemB1, a novel cationic antimicrobial peptide derived from the hemocyanin of Litopenaeus vannamei, induces cancer cell death by targeting mitochondrial voltage-dependent anion channel 1
- Cancer statistics in China and United States, 2022: profiles, trends, and determinants
- Association of preoperative frailty with short- and long-term outcomes after hepatic resection for elderly patients with hepatocellular carcinoma: multicentre analysis
- Notch1 signaling pathway promotes growth and metastasis of gastric cancer via modulating CDH5
- NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL‐6/JAK2/STAT3 pathway activation
- Socioeconomics and attributable etiology of primary liver cancer, 1990-2019
- Colorectal Precancerous Lesions: Molecular Mechanisms, Research Tools, and Natural Product‐Based Clinical Translation
- Impact of malnutrition diagnosed using Global Leadership Initiative on Malnutrition criteria on clinical outcomes of patients with gastric cancer
- Efficient Semi-Supervised Gross Target Volume of Nasopharyngeal Carcinoma Segmentation via Uncertainty Rectified Pyramid Consistency
- Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. [europepmc]
- Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. [europepmc]
- Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. [europepmc]
- Oesophageal cancer. [europepmc]
- Epidemiology of Esophageal Squamous Cell Carcinoma. [europepmc]
- The role of TGF-β/SMAD4 signaling in cancer. [europepmc]
- Cancer incidence and mortality in China, 2014. [europepmc]
- Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. [europepmc]
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. [europepmc]
- Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. [europepmc]
- Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. [europepmc]
- Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. [europepmc]
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [europepmc]
- The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. [europepmc]
- Role of hypoxia in cancer therapy by regulating the tumor microenvironment. [europepmc]
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. [europepmc]
- Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. [europepmc]
- A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks. [europepmc]
- Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. [europepmc]
- Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. [europepmc]
- Cancer statistics in China and United States, 2022: profiles, trends, and determinants. [europepmc]
- Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. [europepmc]
- Physical activity, exercise, and chronic diseases: A brief review. [europepmc]
- Role of pyroptosis in inflammation and cancer. [europepmc]
- Global burden of primary liver cancer in 2020 and predictions to 2040. [europepmc]
Related